This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized (from mouse) antibody to Human MET
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
DrugMonitor™ Anti-Emibetuzumab Antibody (VS-1224-YC418)Emibetuzumab has been evaluated in clinical trials for advanced cancer, including renal cell carcinoma, hepatocellular cancer, gastric adenocarcinoma, and non-small cell lung cancer. The DrugMonitor™ Anti-Emibetuzumab Antibody (VS-1224-YC418) is an anti-drug antibody (ADA) against Emibetuzumab. This drug-based antibody is raised in mice immunized with the Emibetuzumab. The anti-Emibetuzumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Emibetuzumab in samples.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-G049E | Anti-MET immunotoxin (Fab)-PE | Cytotoxicity assay, Function study |
There are currently no Customer reviews or questions for AFC-TAB-H24. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.